ABL1 and acute myeloid leukemia: Previous studies on CML biomarkers primarily focused on BCR-ABL transcript levels or somatic mutations (1), which lack specificity in distinguishing CML from other hematologic malignancies (e.g., AML with monocytic differentiation or MDS with fibrosis).